Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1 4Phase 3 2Phase 1/2 2

Status

Terminated 4Recruiting 4Completed 3Active not recruiting 2Unknown 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 1CNS 1

Conditions

Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1Advanced Solid Tumors 1Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation 1

Interventions

Cyclophosphamide 118pembrolizumab 104Specimen Handling 104Magnetic Resonance Spectroscopy 94fludarabine 92Biopsy 77Injections 53Nivolumab 43Bevacizumab 41Fluorouracil 38venetoclax 37Cisplatin 36Paclitaxel 35Carboplatin 35Cetuximab 34Radiotherapy 31Oxaliplatin 30fludarabine phosphate 29Leucovorin 28Gemcitabine 28Drug Therapy 25Ipilimumab 23Immunotherapy, Adoptive 23Azacitidine 23Radiation 21Irinotecan 21Temozolomide 20Doxorubicin 20tislelizumab 19atezolizumab 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Recruiting × sotorasib × Clear all
NCT06807619 2026-05-22

A Study of Sotorasib in People With Brain Tumors

Memorial Sloan Kettering Cancer Center

Phase 1 Recruiting
16 enrolled
CNS

Brain Neoplasms

NCT06249282 2026-04-03

Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer

City of Hope Medical Center

Phase 1 Recruiting
15 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06804824 2026-03-18

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors

Vividion Therapeutics, Inc.

Phase 1 Recruiting
220 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT05815173 2025-12-30

Ladarixin With Sotorasib in Advanced NSCLC

NYU Langone Health

Phase 1 Recruiting
40 enrolled
Thoracic

Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡